Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (31-40 of 283) with videos related to

Pageof 29
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 2, 2023
Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic ReviewHamlet Gasoyan, Mark A Fiala, Michelle Doering, et al.
JCO Clinical Cancer Informatics|December 15, 2018
Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data SetsMark A Fiala, James Dukeman, Sascha A Tuchman, et al.
Leukemia & Lymphoma|May 15, 2015
A phase I study of thymoglobulin for relapsed or refractory multiple myelomaJesse Keller, Mark A Fiala, John Dipersio, et al.
Blood Cancer Journal|May 10, 2023
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort studyHira Mian, Tanya M Wildes, Ravi Vij, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2023
The Dynamics of Financial Toxicity in Multiple MyelomaMark A Fiala, Alice E Silberstein, Mark A Schroeder, et al.
Leukemia & Lymphoma|June 10, 2010
Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplantRavi Vij, George Ansstas, James C Mosley, et al.
Annals of Hematology|September 5, 2018
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 studyDavid Cella, Jan McKendrick, Amber Kudlac, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 29, 2017
Treating Multiple Myeloma Patients With Oral TherapiesShaji K Kumar, Ravi Vij, Stephen J Noga, et al.
Leukemia Research|February 21, 2023
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass studyMichael Slade, Mark Fiala, Sarah Kelley, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Pageof 29

Showing results (31-40 of 283) with videos related to

Sort By:
Pageof 29
Clinical Lymphoma, Myeloma & Leukemia|September 2, 2023
Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic ReviewHamlet Gasoyan, Mark A Fiala, Michelle Doering, et al.
JCO Clinical Cancer Informatics|December 15, 2018
Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data SetsMark A Fiala, James Dukeman, Sascha A Tuchman, et al.
Leukemia & Lymphoma|May 15, 2015
A phase I study of thymoglobulin for relapsed or refractory multiple myelomaJesse Keller, Mark A Fiala, John Dipersio, et al.
Blood Cancer Journal|May 10, 2023
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort studyHira Mian, Tanya M Wildes, Ravi Vij, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2023
The Dynamics of Financial Toxicity in Multiple MyelomaMark A Fiala, Alice E Silberstein, Mark A Schroeder, et al.
Leukemia & Lymphoma|June 10, 2010
Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplantRavi Vij, George Ansstas, James C Mosley, et al.
Annals of Hematology|September 5, 2018
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 studyDavid Cella, Jan McKendrick, Amber Kudlac, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 29, 2017
Treating Multiple Myeloma Patients With Oral TherapiesShaji K Kumar, Ravi Vij, Stephen J Noga, et al.
Leukemia Research|February 21, 2023
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass studyMichael Slade, Mark Fiala, Sarah Kelley, et al.
British Journal of Haematology|September 26, 2015
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple MyelomaAllison Rosenthal, Shaji Kumar, Craig Hofmeister, et al.
Pageof 29